DGAP-News: Cannovum AG / Key word(s): Product Launch 
Cannovum AG enters the full-spectrum cannabis extract market 
2021-06-29 / 08:28 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has signed a supply 
agreement for full-spectrum cannabis extracts through its licensed subsidiary, Cannovum Health eG. The manufacturer is 
a non-European pharmaceutical company with many years of experience in the extraction process. The extracts are 
distributed to pharmacies under Cannovum's own brand. 
Herbal medicines develop their complete effect through the interaction of all herbal substances, the commonly called 
entourage effect. This important mode of action is preserved in cannabis extracts obtained from the full spectrum of 
the plant. 
Cannabis extracts are becoming increasingly important in the market across Europe. In Germany, steady growth is 
emerging over the last three years, with pharmacy purchases of extracts rising from 4.8 liters in 2017 to more than 
1,300 liters in 2020, with the first half of last year alone seeing a 63% growth in purchase volume. 
"We want to supply patients in Germany and Europe with medical cannabis. Full-spectrum extracts play an important role 
in this, because their mode of action and ease of oral application offer another therapeutic option. This allows us to 
cover the full therapeutic spectrum and reach a large patient group," says Pia Marten, CEO of Cannovum AG. 
The inclusion of cannabis extracts in the product portfolio is an important step towards making cannabis-based 
therapies possible across the board. Cannovum supports physicians and pharmacists in caring for patients through a 
complete medical cannabis portfolio. This gives physicians the opportunity to fully customize the therapy for their 
patients, because every patient deserves the best therapy. 
Contact: 
Linda Rasch, IR & PR, Cannovum AG 
Phone +49 30 3982 163 62, linda.rasch@cannovum.com 
Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, 
Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed 
pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The 
company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing 
distribution for simplified and facilitated access to cannabis-based therapies. 
For more information, visit www.cannovum.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-29 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Cannovum AG 
              Rheinsberger Str. 76/77 
              10115 Berlin 
              Germany 
Phone:        +49 (0)30 3982 16360 
E-mail:       ir@cannovum.com 
Internet:     www.cannovum.com 
ISIN:         DE000A2LQU21 
WKN:          A2LQU2 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich 
EQS News ID:  1212956 
 
End of News   DGAP News Service 
=------------

1212956 2021-06-29


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1212956&application_name=news

(END) Dow Jones Newswires

June 29, 2021 02:30 ET (06:30 GMT)